Multiple Myeloma Treatment in the US: Options, Care Teams and Questions to Ask

Multiple myeloma is a cancer of plasma cells in the bone marrow. It accounts for roughly 10 percent of all blood cancers diagnosed in the United States each year. While it remains a complex condition, advances in medical research have significantly expanded the range of available treatments, and many patients are living longer, more active lives than ever before.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

What Are the Main Multiple Myeloma Treatment Options?

Multiple myeloma treatment options vary depending on the stage of disease, a patient’s overall health, and whether a stem cell transplant is a possibility. Treatment is rarely a single approach. Most patients receive a combination of therapies designed to control the disease, manage symptoms, and preserve quality of life. Standard approaches include chemotherapy, immunotherapy, targeted therapy, steroids, and in eligible patients, autologous stem cell transplantation. Maintenance therapy is often recommended after initial treatment to delay relapse.

How Has Multiple Myeloma Therapy Changed in Recent Years?

New multiple myeloma treatments have reshaped the clinical landscape over the past decade. Monoclonal antibodies such as daratumumab and elotuzumab have become standard parts of many treatment regimens. CAR-T cell therapy, a form of immunotherapy where a patient’s own immune cells are engineered to fight cancer, has received FDA approval for relapsed or refractory multiple myeloma. Bispecific antibodies represent another emerging class, designed to direct immune cells toward myeloma cells with greater precision. These advances have extended the range of multiple myeloma therapy choices, particularly for patients who have experienced relapse.

What Medications Are Commonly Used?

Multiple myeloma medications generally fall into several categories. Proteasome inhibitors, including bortezomib, carfilzomib, and ixazomib, interfere with the protein-clearing process that myeloma cells rely on to survive. Immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide help stimulate the immune system and disrupt tumor cell activity. Corticosteroids like dexamethasone are frequently combined with other agents to enhance effectiveness. Histone deacetylase inhibitors and nuclear export inhibitors have also been approved for specific treatment settings. Your oncologist will consider your specific disease profile when recommending a combination.

Who Is on a Multiple Myeloma Care Team?

Care for multiple myeloma typically involves a multidisciplinary team. A hematologist-oncologist leads the treatment plan, while a radiation oncologist may be involved if localized tumors require radiation. Transplant specialists, pharmacists, nurses, social workers, and palliative care professionals all play roles depending on the phase of treatment. Major academic medical centers and cancer centers across the US, including those designated by the National Cancer Institute, often have specialized myeloma programs with dedicated teams and access to emerging therapies.

Are Multiple Myeloma Clinical Trials Worth Considering?

Multiple myeloma clinical trials offer patients access to investigational treatments before they become widely available. Participation in a clinical trial can be a viable option, particularly for patients with relapsed or refractory disease who have exhausted standard therapies. Trials are available across the US through institutions registered with ClinicalTrials.gov, and eligibility criteria vary. Discussing clinical trial options with your oncologist early in the treatment process ensures you have a complete picture of what is available to you.

Questions to Ask Your Medical Team

Being prepared with the right questions can help patients and caregivers feel more in control of the care process. Consider asking about which treatment combination is recommended and why, what the expected response rate is, how treatment will be monitored, what side effects to anticipate, and whether a clinical trial might be appropriate. It is also reasonable to ask about fertility preservation before starting treatment, as some therapies can affect reproductive health. Requesting a second opinion from a myeloma specialist is widely considered acceptable and often encouraged.

Multiple myeloma is a condition that demands ongoing management and regular reassessment. With a knowledgeable care team, a clear understanding of available multiple myeloma treatment options, and active involvement in decision-making, patients are better positioned to navigate each phase of treatment with clarity and confidence.